Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...

Key Takeaways Wedbush upgraded Snowflake as the analysts predicted that the artificial intelligence software era is ...

Major technology stocks are positioned for a strong year-end rally as artificial intelligence initiatives accelerate and ...

Wedbush notes that in the past two weeks Kioxia filed for an IPO and SanDisk released its 10-12B, telling investors that data from these ...

Power needs for artificial intelligence and cloud computing are expanding so rapidly that some data center campuses may use ...

Apple, Inc. ($AAPL) shares have gained about 24% this year, roughly in line with the broader S&P 500’s 26%+ advance. The year ...

Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s TRACER platform. The investment firm said it believes TRACER alone should ...

A potential Trump administration may ease regulations for self-driving vehicles, accelerating Tesla's progress ...

The EV maker’s stock gained 3.7% on Friday, leaving the shares ahead nearly 40% for the year and giving it a market value of ...

Apple Inc.’s skeptics and bears have missed the last more than $1 trillion upward move in the stock by overlooking three key dynamics behind the story, Wedbush analysts said Friday. Apple has an ...

Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the name. The firm added the company’s tau antibody for ...